Intrynsic
Sign In
Sector HubStock AnalysisScreener
Sign InCreate Account
  1. Home
  2. /
  3. Stocks
  4. /
  5. Divi's Laboratories Limited

Healthcare · NSE: DIVISLAB

Divi's Laboratories Limited - Share Price, Charts & Financials

Fair value estimate

We don't have a reliable fair-value estimate for Divi's Laboratories Limited yet - our models need more data before we'll publish a number. You can run the valuation with your own assumptions in the Valuation tab, or try the free intrinsic-value calculator.

Ask AI about DIVISLAB

About Divi's Laboratories Limited

Divi's Laboratories makes active pharmaceutical ingredients and custom-synthesis products for global drug companies. Its earnings depend on manufacturing efficiency and long-term supply contracts with large pharma clients.

Key numbers & health

Revenue
₹10.6K Cr

FY26

Net profit
₹2.6K Cr

FY26

EPS
₹96.73

FY26

Free cash flow
₹218 Cr

FY26

GrowthRevenue +10.8%/yr (3y) · +11.2%/yr (9y)Good

Over the last 3 years, revenue grew 10.8%/yr and profit grew 12.1%/yr. Over 9 years, revenue grew 11.2%/yr and profit 10.3%/yr.

ProfitabilityROE 15.3%Good

Every ₹100 of shareholder money earned ₹15.3 in profit last year, vs a sector median of 10.2%.

DebtD/E 0.00Good

It holds more cash than debt.

ValuationP/E 115.3 vs sector 36.8Weak

It trades at 115.3x earnings against a sector median of 36.8x.

Quality₹16 cash per ₹100 profitOkay

About ₹16 of every ₹100 of reported profit turned into free cash (median, last 5 years); operating cash flow was positive in 5 of 5 years.

Peers

Sun Pharmaceutical Industries Limited₹4,48,988 CrP/E 39.1ROE 13.8%Fair-value estimate →Torrent Pharmaceuticals Limited₹1,56,057 CrP/E 72.1ROE 25.5%Fair-value estimate →Cipla Limited₹1,14,487 CrP/E 29.5ROE 11.2%Fair-value estimate →
Ask AI about Divi's Laboratories LimitedChat with Intrynsic's research agent about results, risks and filings.Sign up free →Track it in your watchlistFair-value alerts, result-day briefs and portfolio analytics.Sign up free →See the full model workingsEvery assumption, per-model trace, reverse DCF and peer lens.Sign up free →

Frequently asked questions

What does Divi's Laboratories Limited do?

Divi's Laboratories makes active pharmaceutical ingredients and custom-synthesis products for global drug companies. Its earnings depend on manufacturing efficiency and long-term supply contracts with large pharma clients.

Which sector does Divi's Laboratories Limited belong to?

Divi's Laboratories Limited operates in the Healthcare sector (Healthcare Services industry) and is listed on the NSE as DIVISLAB.

What is Divi's Laboratories Limited's latest annual revenue and profit?

For FY2017, Divi's Laboratories Limited reported revenue of ₹4,064 Cr and net profit of ₹1,060 Cr. The full multi-year history is in the Financials section above.

What are Divi's Laboratories Limited's EPS and return on equity?

In FY2017, Divi's Laboratories Limited recorded earnings per share of ₹40.0 and a return on equity of 19.8%.

How much debt does Divi's Laboratories Limited carry?

Divi's Laboratories Limited reported total debt of ₹36 Cr in FY2017. See the balance-sheet trend in the Financials section for context.

Disclaimer: Intrynsic provides educational and informational analysis only. Fair-value figures are estimates based on stated assumptions- they are not investment advice, research recommendations, or an offer to transact in any security. The models rely on assumptions (discount rates, growth, multiples) that may prove wrong and on past financials, which do not guarantee future results; prices also move on macro factors the models don't capture. Intrynsic is not a SEBI-registered investment adviser or research analyst. Markets carry risk; please do your own research or consult a registered adviser before making investment decisions. Prices shown may be delayed end-of-day values. Terms · Privacy

Intrynsic

Indian Equity Research Assistant. Built for serious investors.

Research

  • Sector Hub
  • Stock Analysis
  • Screener
  • Videos
  • IV Calculator
  • Spotlight
  • Market Signals
  • Macro Analysis
  • News
  • Announcements
  • AI Research
  • Watchlist
  • Portfolio

Product

  • Features
  • How it Works
  • About
  • Plans
  • FAQ
  • Compare
  • Blog
  • Knowledge Base

Legal

  • Privacy Policy
  • Terms of Service

Support

  • Contact Us
  • How it Works

Stay Updated

Get the latest news and updates delivered to your inbox.

Enter your emailEnter your email

© 2026–27 Intrynsic. All rights reserved.
Intrynsic is a product of FINTERVUE.IO Private Limited.
For informational purposes only. Not investment advice.

Built with ♥ for India